Kiadis Pharma is a biopharmaceutical company based in Amsterdam, The Netherlands. We focus on the treatment of blood cancers and inherited blood disorders aiming to make bone marrow transplantations, a risky procedure that is often the last hope for patients, safer and more efficient. This means we have a passionate team that is dedicated to make a huge difference for patients. If you are up to the challenge and would like to be part of our team, we are currently looking for a Technician Bioassay Development and QC.
As a Technician Bioassay Development and QC at Kiadis Pharma, you will:
- Independently perform and analyze cell-based assays, mainly by flow cytometry and ELISA
- Develop/improve bioanalytical methods in close collaboration with scientists
- Be involved in method validations under GMP and product release testing
- Writing of SOPs and other lab-related documents
The ideal candidate
- Holds an HBO / Bachelor in cell biology, immunology, hematology, or related fields
- Has at least 2 years of experience in a laboratory environment within the pharmaceutical / biotech industry
- Excellent knowledge of biological assays, immunology and cell culture
- Affinity with QC testing under GMP according to standard operating procedures, assay development or assay validations would be a plus
- The candidate is a good team player with strong communication skills
A challenging position in an innovative, fast growing, biotechnology company. Working in a fast-paced dynamic environment brings the opportunity to make your own mark within the organization.
You will be rewarded a competitive remuneration package, the opportunity for personal development and to contribute to make a huge difference for patients.
For further information, please contact Jeroen Elderhorst, HR Manager, by phone at +31 (0)20 240 5250. You can e-mail your motivation letter and resume to firstname.lastname@example.org.
Kiadis Pharma’s allodepleted T-cell immunotherapy product candidate, given after a haploidentical hematopoietic stem cell transplantation (HSCT), is designed to reduce Graft versus Host Disease (GVHD). Single dose Phase 2 data with lead product candidate ATIR101 in patients with blood cancer shows a strong and clinically very relevant improvement over literature for the Baltimore protocol, with reduced risk of GVHD. Based on the positive results from the Phase 2 trial, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101 across the EU as an adjunctive treatment in HSCT for malignant disease. Kiadis Pharma submitted responses to the Day 120 List of Questions in March 2018 and is on track to potentially obtain a positive CHMP opinion for ATIR101 in Q4 2018 and (conditional) approval from the European Commission in Q1 2019, which would allow for a European launch in H2 2019. Kiadis Pharma is conducting a Phase 3 trial with ATIR101 across Europe and North America (head to head against the Baltimore protocol). The first patient was enrolled in December 2017.
In September 2017 the US Food and Drug Administration (FDA) granted ATIR101 the Regenerative Medicine Advanced Therapy (RMAT) designation. ATIR101 has been granted Orphan Drug Designations both in the US and Europe.